Noxopharm Ltd has released a press release.
Veyonda and Immuno-Oncology Effect Explained
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- Idronoxil Confirmed as New Immuno-Oncology Drug
- Veyonda Chemotherapy Enhancement Program to be Expanded
- KZA: Kazia sells stake in Noxopharm
- Noxopharm to expedite Veyonda Clinical Program
- FNN interview with Nox Chief Medical Officer on Interim Data
Later from Noxopharm
- DARRT Treatment Has Lasting Disease Control at Six Months
- LuPIN Trial Demonstrates High Rates of Response
- Promising Data Leads to Expansion of LuPIN Trial
- Conference Hears of Positive Interim Data from LuPIN Trial
- NOX Announces AU$26 Million Funding Facility
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm